Impax To Cease Marketing Practices For Lipram-CR Under Settlement With Solvay
This article was originally published in The Pink Sheet Daily
Settlement requires that Impax cease marketing practices implying Lipram-CR is a generic equivalent to Creon branded products.
You may also be interested in...
The firm's Pancrease MT pancreatic enzyme product will remain on the market.
The firm’s acute migraine treatment Nurtec ODT generated $65m in 2020 after launching a year ago. Biohaven aims for Nurtec to become the leader in what could be a $4bn-$5bn category in the US.
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.